Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mouth Neoplasms | 7 | 2023 | 194 | 3.080 |
Why?
|
Head and Neck Neoplasms | 12 | 2024 | 1051 | 2.240 |
Why?
|
Carcinoma, Squamous Cell | 9 | 2023 | 1075 | 1.950 |
Why?
|
Cell Transformation, Neoplastic | 5 | 2015 | 427 | 1.720 |
Why?
|
Adaptor Proteins, Signal Transducing | 9 | 2020 | 302 | 1.640 |
Why?
|
Saliva | 2 | 2021 | 122 | 1.480 |
Why?
|
ErbB Receptors | 8 | 2020 | 485 | 1.470 |
Why?
|
Carcinoma, Adenoid Cystic | 2 | 2022 | 28 | 1.010 |
Why?
|
Tumor Suppressor Proteins | 3 | 2015 | 279 | 0.980 |
Why?
|
Salivary Gland Neoplasms | 2 | 2022 | 66 | 0.960 |
Why?
|
Papillomavirus Infections | 6 | 2023 | 239 | 0.940 |
Why?
|
Xenograft Model Antitumor Assays | 7 | 2020 | 458 | 0.910 |
Why?
|
Nasopharyngeal Neoplasms | 1 | 2023 | 47 | 0.900 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2023 | 50 | 0.900 |
Why?
|
Liquid Biopsy | 1 | 2021 | 33 | 0.830 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2021 | 70 | 0.810 |
Why?
|
Early Detection of Cancer | 2 | 2023 | 387 | 0.800 |
Why?
|
Drug Discovery | 3 | 2022 | 103 | 0.770 |
Why?
|
Lung Neoplasms | 8 | 2017 | 2260 | 0.760 |
Why?
|
Mutation | 6 | 2020 | 3952 | 0.750 |
Why?
|
DNA, Neoplasm | 1 | 2020 | 265 | 0.730 |
Why?
|
Genome, Mitochondrial | 1 | 2019 | 26 | 0.720 |
Why?
|
DNA Methylation | 7 | 2020 | 622 | 0.710 |
Why?
|
Gene Expression Regulation, Neoplastic | 10 | 2020 | 1196 | 0.700 |
Why?
|
Heterografts | 2 | 2017 | 98 | 0.690 |
Why?
|
DNA, Mitochondrial | 1 | 2019 | 183 | 0.690 |
Why?
|
Transforming Growth Factor beta | 3 | 2018 | 298 | 0.690 |
Why?
|
Point Mutation | 1 | 2019 | 246 | 0.680 |
Why?
|
Glutathione Transferase | 1 | 2019 | 111 | 0.670 |
Why?
|
Receptor, Notch1 | 3 | 2020 | 85 | 0.660 |
Why?
|
Biomarkers, Tumor | 6 | 2022 | 1461 | 0.660 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2018 | 589 | 0.640 |
Why?
|
Adenocarcinoma | 2 | 2015 | 1160 | 0.640 |
Why?
|
Papillomaviridae | 6 | 2022 | 153 | 0.630 |
Why?
|
Epithelial-Mesenchymal Transition | 2 | 2015 | 69 | 0.610 |
Why?
|
Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 105 | 0.610 |
Why?
|
Humans | 56 | 2024 | 86281 | 0.570 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 153 | 0.560 |
Why?
|
Oropharyngeal Neoplasms | 3 | 2022 | 118 | 0.550 |
Why?
|
MicroRNAs | 3 | 2015 | 534 | 0.530 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 1305 | 0.530 |
Why?
|
Mammary Neoplasms, Experimental | 3 | 2013 | 124 | 0.520 |
Why?
|
Protein Kinase Inhibitors | 5 | 2018 | 589 | 0.520 |
Why?
|
Leukoplakia, Oral | 1 | 2014 | 11 | 0.520 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2020 | 380 | 0.520 |
Why?
|
Histone-Lysine N-Methyltransferase | 3 | 2022 | 154 | 0.520 |
Why?
|
Mouth Mucosa | 1 | 2014 | 66 | 0.500 |
Why?
|
Signal Transduction | 10 | 2022 | 3233 | 0.500 |
Why?
|
Neoplasms | 5 | 2023 | 2889 | 0.470 |
Why?
|
DNA | 2 | 2019 | 1293 | 0.470 |
Why?
|
Methylnitronitrosoguanidine | 1 | 2012 | 16 | 0.450 |
Why?
|
Exodeoxyribonucleases | 1 | 2012 | 14 | 0.450 |
Why?
|
Animals | 23 | 2023 | 26518 | 0.440 |
Why?
|
DNA Mismatch Repair | 1 | 2012 | 52 | 0.440 |
Why?
|
DNA Repair Enzymes | 1 | 2012 | 52 | 0.430 |
Why?
|
Neoplasm Invasiveness | 6 | 2021 | 551 | 0.420 |
Why?
|
DNA, Viral | 2 | 2023 | 265 | 0.410 |
Why?
|
Artificial Intelligence | 3 | 2023 | 294 | 0.400 |
Why?
|
Repressor Proteins | 4 | 2022 | 403 | 0.400 |
Why?
|
Histones | 3 | 2020 | 309 | 0.390 |
Why?
|
Mice | 16 | 2021 | 11313 | 0.380 |
Why?
|
Middle Aged | 18 | 2024 | 24957 | 0.380 |
Why?
|
Fibroblasts | 2 | 2012 | 729 | 0.370 |
Why?
|
Proto-Oncogene Proteins c-akt | 4 | 2024 | 321 | 0.370 |
Why?
|
Lung | 2 | 2015 | 1167 | 0.360 |
Why?
|
Neoplastic Stem Cells | 3 | 2020 | 143 | 0.360 |
Why?
|
Cell Proliferation | 9 | 2020 | 1571 | 0.360 |
Why?
|
Cell Line, Tumor | 11 | 2024 | 2421 | 0.350 |
Why?
|
High-Throughput Nucleotide Sequencing | 5 | 2022 | 455 | 0.350 |
Why?
|
Male | 21 | 2023 | 40860 | 0.350 |
Why?
|
Female | 25 | 2024 | 44405 | 0.340 |
Why?
|
Lymphatic Metastasis | 2 | 2021 | 480 | 0.340 |
Why?
|
Carcinoma | 2 | 2022 | 434 | 0.330 |
Why?
|
Antineoplastic Agents | 3 | 2016 | 2351 | 0.310 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2017 | 1073 | 0.290 |
Why?
|
Quinolones | 2 | 2024 | 60 | 0.280 |
Why?
|
Proteins | 2 | 2022 | 777 | 0.280 |
Why?
|
Tumor Microenvironment | 4 | 2024 | 415 | 0.270 |
Why?
|
Epigenesis, Genetic | 5 | 2020 | 476 | 0.270 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 4 | 2021 | 877 | 0.250 |
Why?
|
Adult | 11 | 2022 | 25577 | 0.250 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2020 | 376 | 0.240 |
Why?
|
Cisplatin | 2 | 2022 | 612 | 0.230 |
Why?
|
Clone Cells | 3 | 2021 | 213 | 0.220 |
Why?
|
Herpesvirus 4, Human | 1 | 2023 | 114 | 0.220 |
Why?
|
Re-Irradiation | 1 | 2022 | 15 | 0.220 |
Why?
|
Chromatin | 2 | 2017 | 378 | 0.220 |
Why?
|
Neoplasm Transplantation | 3 | 2017 | 391 | 0.220 |
Why?
|
Caenorhabditis elegans Proteins | 1 | 2023 | 108 | 0.220 |
Why?
|
Real-Time Polymerase Chain Reaction | 2 | 2021 | 272 | 0.220 |
Why?
|
Organoids | 1 | 2022 | 60 | 0.210 |
Why?
|
Gene Silencing | 3 | 2018 | 172 | 0.210 |
Why?
|
Aged | 9 | 2019 | 18353 | 0.210 |
Why?
|
Tissue Distribution | 1 | 2022 | 290 | 0.210 |
Why?
|
Amyloid Precursor Protein Secretases | 1 | 2022 | 93 | 0.210 |
Why?
|
Receptors, Notch | 1 | 2022 | 119 | 0.210 |
Why?
|
Cloud Computing | 1 | 2021 | 11 | 0.200 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2021 | 39 | 0.200 |
Why?
|
T-Lymphocytes, Regulatory | 2 | 2021 | 295 | 0.200 |
Why?
|
Models, Animal | 1 | 2022 | 261 | 0.200 |
Why?
|
Drug Monitoring | 1 | 2022 | 118 | 0.200 |
Why?
|
Sarcoma | 1 | 2022 | 211 | 0.190 |
Why?
|
Kelch-Like ECH-Associated Protein 1 | 1 | 2020 | 11 | 0.190 |
Why?
|
Proteasome Inhibitors | 1 | 2020 | 50 | 0.190 |
Why?
|
Cell-Free Nucleic Acids | 1 | 2022 | 69 | 0.190 |
Why?
|
Viral Load | 1 | 2021 | 148 | 0.190 |
Why?
|
B7-H1 Antigen | 2 | 2019 | 250 | 0.190 |
Why?
|
Gene Expression Profiling | 5 | 2018 | 1381 | 0.190 |
Why?
|
Disease Progression | 2 | 2015 | 1531 | 0.190 |
Why?
|
NF-E2-Related Factor 2 | 1 | 2020 | 41 | 0.190 |
Why?
|
Cohort Studies | 5 | 2018 | 2759 | 0.190 |
Why?
|
Computational Biology | 2 | 2021 | 528 | 0.190 |
Why?
|
Esthesioneuroblastoma, Olfactory | 1 | 2019 | 2 | 0.180 |
Why?
|
User-Computer Interface | 1 | 2021 | 185 | 0.180 |
Why?
|
RNA, Viral | 1 | 2021 | 327 | 0.180 |
Why?
|
Serine Endopeptidases | 1 | 2020 | 145 | 0.180 |
Why?
|
Reproducibility of Results | 4 | 2019 | 2699 | 0.180 |
Why?
|
Genetic Heterogeneity | 1 | 2019 | 62 | 0.180 |
Why?
|
Polymerase Chain Reaction | 3 | 2017 | 927 | 0.180 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2021 | 556 | 0.180 |
Why?
|
Transcriptome | 2 | 2021 | 574 | 0.180 |
Why?
|
Enzyme Inhibitors | 1 | 2022 | 632 | 0.170 |
Why?
|
Glutathione S-Transferase pi | 1 | 2019 | 18 | 0.170 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2020 | 164 | 0.170 |
Why?
|
Mice, Inbred NOD | 4 | 2020 | 187 | 0.170 |
Why?
|
Databases, Genetic | 1 | 2019 | 259 | 0.160 |
Why?
|
G2 Phase Cell Cycle Checkpoints | 2 | 2020 | 11 | 0.160 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 2434 | 0.160 |
Why?
|
Virus Integration | 1 | 2017 | 16 | 0.160 |
Why?
|
Prognosis | 6 | 2022 | 3669 | 0.160 |
Why?
|
Lung Diseases, Obstructive | 1 | 2017 | 19 | 0.150 |
Why?
|
Smad4 Protein | 1 | 2017 | 23 | 0.150 |
Why?
|
Betacoronavirus | 1 | 2020 | 258 | 0.150 |
Why?
|
Nuclear Proteins | 2 | 2022 | 694 | 0.150 |
Why?
|
Cellular Senescence | 1 | 2017 | 94 | 0.150 |
Why?
|
Estrogen Receptor beta | 1 | 2017 | 25 | 0.150 |
Why?
|
Laryngeal Neoplasms | 1 | 2017 | 89 | 0.150 |
Why?
|
Mice, SCID | 4 | 2020 | 252 | 0.150 |
Why?
|
p21-Activated Kinases | 1 | 2016 | 15 | 0.150 |
Why?
|
Carcinogenesis | 2 | 2022 | 194 | 0.150 |
Why?
|
Multiple Myeloma | 1 | 2020 | 307 | 0.150 |
Why?
|
Bone Marrow Cells | 1 | 2017 | 253 | 0.140 |
Why?
|
Smoke | 1 | 2016 | 27 | 0.140 |
Why?
|
Gene Fusion | 1 | 2016 | 38 | 0.140 |
Why?
|
Glaucoma, Open-Angle | 1 | 2016 | 17 | 0.140 |
Why?
|
Neoplasm Proteins | 1 | 2020 | 532 | 0.140 |
Why?
|
Immunotherapy | 2 | 2020 | 627 | 0.140 |
Why?
|
Mammary Tumor Virus, Mouse | 3 | 2013 | 63 | 0.140 |
Why?
|
Aged, 80 and over | 4 | 2019 | 6481 | 0.140 |
Why?
|
Adenocarcinoma in Situ | 1 | 2015 | 4 | 0.140 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2016 | 128 | 0.140 |
Why?
|
Antibodies | 1 | 2018 | 349 | 0.140 |
Why?
|
Promoter Regions, Genetic | 2 | 2017 | 937 | 0.140 |
Why?
|
Estrogen Receptor alpha | 1 | 2017 | 144 | 0.140 |
Why?
|
Extracellular Matrix Proteins | 1 | 2016 | 123 | 0.140 |
Why?
|
Translocation, Genetic | 1 | 2016 | 265 | 0.140 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2017 | 378 | 0.130 |
Why?
|
Hyperplasia | 1 | 2015 | 148 | 0.130 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 526 | 0.130 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 316 | 0.130 |
Why?
|
Coronavirus Infections | 1 | 2020 | 301 | 0.130 |
Why?
|
Patients | 1 | 2016 | 100 | 0.130 |
Why?
|
RNA Interference | 2 | 2013 | 368 | 0.130 |
Why?
|
Pulmonary Fibrosis | 1 | 2016 | 123 | 0.130 |
Why?
|
Anticarcinogenic Agents | 2 | 2006 | 70 | 0.130 |
Why?
|
Protein Interaction Mapping | 2 | 2012 | 82 | 0.120 |
Why?
|
Paclitaxel | 3 | 2022 | 460 | 0.120 |
Why?
|
Quality of Life | 1 | 2022 | 1575 | 0.120 |
Why?
|
Species Specificity | 1 | 2016 | 678 | 0.120 |
Why?
|
Cell Survival | 2 | 2016 | 966 | 0.120 |
Why?
|
Genome, Human | 2 | 2017 | 756 | 0.120 |
Why?
|
China | 1 | 2014 | 228 | 0.120 |
Why?
|
Precancerous Conditions | 1 | 2015 | 196 | 0.120 |
Why?
|
Liver Cirrhosis | 1 | 2016 | 296 | 0.120 |
Why?
|
Melanoma | 1 | 2018 | 454 | 0.120 |
Why?
|
Organ Specificity | 1 | 2014 | 257 | 0.120 |
Why?
|
Mitochondria | 1 | 2017 | 535 | 0.120 |
Why?
|
Genetic Vectors | 2 | 2012 | 438 | 0.110 |
Why?
|
Checkpoint Kinase 1 | 1 | 2012 | 13 | 0.110 |
Why?
|
Cell Movement | 3 | 2015 | 756 | 0.110 |
Why?
|
Base Pair Mismatch | 1 | 2012 | 27 | 0.110 |
Why?
|
Urinary Bladder | 1 | 2015 | 236 | 0.110 |
Why?
|
Alkylating Agents | 1 | 2012 | 32 | 0.110 |
Why?
|
MutS Homolog 2 Protein | 1 | 2012 | 30 | 0.110 |
Why?
|
Enzyme Activation | 1 | 2014 | 692 | 0.110 |
Why?
|
Genomics | 1 | 2018 | 710 | 0.110 |
Why?
|
Neoplasm Staging | 4 | 2022 | 1932 | 0.110 |
Why?
|
Computer Simulation | 1 | 2016 | 1077 | 0.110 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2012 | 279 | 0.110 |
Why?
|
DNA, Complementary | 1 | 2012 | 393 | 0.100 |
Why?
|
Algorithms | 2 | 2018 | 1828 | 0.100 |
Why?
|
Arsenic | 1 | 2015 | 251 | 0.100 |
Why?
|
Ovarian Neoplasms | 1 | 2018 | 738 | 0.100 |
Why?
|
Cloning, Molecular | 1 | 2012 | 646 | 0.100 |
Why?
|
Protein Kinases | 1 | 2012 | 209 | 0.100 |
Why?
|
Carboplatin | 2 | 2022 | 286 | 0.100 |
Why?
|
Transfection | 1 | 2012 | 895 | 0.100 |
Why?
|
Recombinant Proteins | 1 | 2012 | 1014 | 0.090 |
Why?
|
Mammary Glands, Animal | 1 | 2010 | 78 | 0.090 |
Why?
|
Biomarkers | 1 | 2016 | 1709 | 0.090 |
Why?
|
Thiazoles | 1 | 2010 | 131 | 0.090 |
Why?
|
Apoptosis | 4 | 2020 | 1678 | 0.090 |
Why?
|
Focal Adhesion Kinase 1 | 1 | 2009 | 31 | 0.090 |
Why?
|
Phenotype | 2 | 2014 | 2375 | 0.090 |
Why?
|
Tumor Cells, Cultured | 3 | 2020 | 1040 | 0.090 |
Why?
|
Immunoenzyme Techniques | 3 | 2015 | 303 | 0.090 |
Why?
|
Tumor Burden | 2 | 2020 | 288 | 0.090 |
Why?
|
Mice, Inbred C57BL | 2 | 2021 | 3087 | 0.090 |
Why?
|
Chemoradiotherapy | 2 | 2022 | 301 | 0.090 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2011 | 274 | 0.080 |
Why?
|
Phosphatidylinositol 3-Kinases | 2 | 2024 | 262 | 0.080 |
Why?
|
Pancreatic Neoplasms | 1 | 2014 | 645 | 0.080 |
Why?
|
Pyrimidines | 1 | 2010 | 370 | 0.080 |
Why?
|
Cetuximab | 2 | 2018 | 113 | 0.080 |
Why?
|
Disease Models, Animal | 1 | 2014 | 2227 | 0.080 |
Why?
|
Breast Neoplasms | 2 | 2018 | 2881 | 0.070 |
Why?
|
Two-Hybrid System Techniques | 1 | 2007 | 55 | 0.070 |
Why?
|
Rosmarinus | 1 | 2006 | 1 | 0.070 |
Why?
|
Leukemia, Myelomonocytic, Acute | 1 | 2006 | 5 | 0.070 |
Why?
|
Leukemia, Experimental | 1 | 2006 | 15 | 0.070 |
Why?
|
Blotting, Western | 3 | 2015 | 781 | 0.070 |
Why?
|
Cholecalciferol | 1 | 2006 | 35 | 0.070 |
Why?
|
TOR Serine-Threonine Kinases | 2 | 2020 | 182 | 0.070 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 1708 | 0.070 |
Why?
|
ROC Curve | 2 | 2017 | 752 | 0.060 |
Why?
|
Plant Extracts | 1 | 2006 | 243 | 0.060 |
Why?
|
Carotenoids | 1 | 2003 | 14 | 0.060 |
Why?
|
Histone Demethylases | 1 | 2023 | 30 | 0.060 |
Why?
|
Longevity | 1 | 2023 | 51 | 0.060 |
Why?
|
Case-Control Studies | 2 | 2020 | 1801 | 0.060 |
Why?
|
Centrioles | 1 | 2022 | 4 | 0.060 |
Why?
|
Bacteria | 2 | 2023 | 445 | 0.060 |
Why?
|
Antioxidants | 1 | 2003 | 223 | 0.050 |
Why?
|
Mice, Knockout | 2 | 2020 | 1918 | 0.050 |
Why?
|
Drug Repositioning | 1 | 2022 | 22 | 0.050 |
Why?
|
Hydroxyurea | 1 | 2022 | 239 | 0.050 |
Why?
|
Amino Acid Sequence | 2 | 2021 | 2062 | 0.050 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2023 | 241 | 0.050 |
Why?
|
Albumins | 1 | 2022 | 133 | 0.050 |
Why?
|
4-Nitroquinoline-1-oxide | 1 | 2021 | 15 | 0.050 |
Why?
|
Treatment Outcome | 3 | 2022 | 7949 | 0.050 |
Why?
|
Maximum Tolerated Dose | 1 | 2022 | 270 | 0.050 |
Why?
|
Caenorhabditis elegans | 1 | 2023 | 222 | 0.050 |
Why?
|
Lymphocyte Count | 1 | 2021 | 94 | 0.050 |
Why?
|
Lymphocyte Depletion | 1 | 2021 | 97 | 0.050 |
Why?
|
Alphapapillomavirus | 1 | 2021 | 45 | 0.050 |
Why?
|
Carcinogens | 1 | 2021 | 108 | 0.050 |
Why?
|
Cells, Cultured | 2 | 2017 | 2810 | 0.050 |
Why?
|
Prospective Studies | 2 | 2022 | 4194 | 0.050 |
Why?
|
Induction Chemotherapy | 1 | 2022 | 147 | 0.050 |
Why?
|
Administration, Intravenous | 1 | 2020 | 50 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2020 | 3616 | 0.050 |
Why?
|
Biological Availability | 1 | 2020 | 92 | 0.050 |
Why?
|
Bortezomib | 1 | 2020 | 75 | 0.050 |
Why?
|
Fluorouracil | 1 | 2022 | 556 | 0.050 |
Why?
|
DNA Repair | 1 | 2022 | 356 | 0.050 |
Why?
|
Endoplasmic Reticulum Stress | 1 | 2020 | 83 | 0.050 |
Why?
|
Phosphatidylinositol 3-Kinase | 1 | 2020 | 14 | 0.050 |
Why?
|
Oncogene Protein v-akt | 1 | 2020 | 21 | 0.050 |
Why?
|
Nose Neoplasms | 1 | 2019 | 31 | 0.050 |
Why?
|
Cyclin D1 | 1 | 2020 | 83 | 0.050 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2020 | 199 | 0.040 |
Why?
|
Retinoblastoma Protein | 1 | 2020 | 66 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2022 | 751 | 0.040 |
Why?
|
Antigens, Neoplasm | 1 | 2021 | 324 | 0.040 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 104 | 0.040 |
Why?
|
Colon | 1 | 2022 | 495 | 0.040 |
Why?
|
Transplantation, Heterologous | 1 | 2020 | 363 | 0.040 |
Why?
|
Base Sequence | 2 | 2017 | 2329 | 0.040 |
Why?
|
Administration, Oral | 1 | 2020 | 683 | 0.040 |
Why?
|
Time Factors | 2 | 2018 | 5198 | 0.040 |
Why?
|
Transcription, Genetic | 1 | 2003 | 1135 | 0.040 |
Why?
|
Aging | 1 | 2023 | 689 | 0.040 |
Why?
|
Cystadenoma | 1 | 2018 | 19 | 0.040 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2018 | 19 | 0.040 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 19 | 0.040 |
Why?
|
Programmed Cell Death 1 Receptor | 1 | 2019 | 159 | 0.040 |
Why?
|
HEK293 Cells | 1 | 2020 | 615 | 0.040 |
Why?
|
beta Catenin | 1 | 2020 | 250 | 0.040 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2018 | 40 | 0.040 |
Why?
|
beta-Galactosidase | 1 | 2017 | 71 | 0.040 |
Why?
|
Peptides | 1 | 2021 | 639 | 0.040 |
Why?
|
Risk Factors | 2 | 2021 | 5397 | 0.040 |
Why?
|
Ki-67 Antigen | 1 | 2017 | 64 | 0.040 |
Why?
|
X-Rays | 1 | 2017 | 130 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2017 | 188 | 0.040 |
Why?
|
CTLA-4 Antigen | 1 | 2018 | 135 | 0.040 |
Why?
|
Th17 Cells | 1 | 2018 | 79 | 0.040 |
Why?
|
CD146 Antigen | 1 | 2017 | 4 | 0.040 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2017 | 36 | 0.040 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2017 | 133 | 0.040 |
Why?
|
Epithelium | 1 | 2018 | 317 | 0.040 |
Why?
|
RNA, Messenger | 2 | 2015 | 1975 | 0.040 |
Why?
|
Prostatic Intraepithelial Neoplasia | 1 | 2017 | 21 | 0.040 |
Why?
|
Th1 Cells | 1 | 2018 | 164 | 0.040 |
Why?
|
Forkhead Transcription Factors | 1 | 2018 | 166 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 123 | 0.040 |
Why?
|
Young Adult | 2 | 2022 | 5961 | 0.040 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2016 | 48 | 0.040 |
Why?
|
Trabecular Meshwork | 1 | 2016 | 3 | 0.040 |
Why?
|
Sclera | 1 | 2016 | 11 | 0.040 |
Why?
|
Gene Ontology | 1 | 2016 | 34 | 0.040 |
Why?
|
Aqueous Humor | 1 | 2016 | 23 | 0.040 |
Why?
|
Optic Nerve | 1 | 2016 | 35 | 0.040 |
Why?
|
Survival Rate | 1 | 2020 | 1856 | 0.040 |
Why?
|
Microarray Analysis | 1 | 2016 | 96 | 0.040 |
Why?
|
Intraocular Pressure | 1 | 2016 | 54 | 0.040 |
Why?
|
Datasets as Topic | 1 | 2016 | 71 | 0.040 |
Why?
|
Molecular Sequence Annotation | 1 | 2016 | 67 | 0.040 |
Why?
|
Tobacco Products | 1 | 2016 | 40 | 0.040 |
Why?
|
Area Under Curve | 1 | 2016 | 334 | 0.030 |
Why?
|
Allelic Imbalance | 1 | 2015 | 20 | 0.030 |
Why?
|
Severity of Illness Index | 1 | 2021 | 1796 | 0.030 |
Why?
|
Proteome | 1 | 2016 | 124 | 0.030 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 1056 | 0.030 |
Why?
|
Pyrazoles | 1 | 2016 | 153 | 0.030 |
Why?
|
Immunohistochemistry | 1 | 2019 | 1752 | 0.030 |
Why?
|
Pyrroles | 1 | 2016 | 184 | 0.030 |
Why?
|
Fibrosis | 1 | 2016 | 202 | 0.030 |
Why?
|
Disease-Free Survival | 1 | 2018 | 1203 | 0.030 |
Why?
|
Gene Dosage | 1 | 2015 | 207 | 0.030 |
Why?
|
Prostate-Specific Antigen | 1 | 2017 | 346 | 0.030 |
Why?
|
RNA, Small Interfering | 1 | 2016 | 547 | 0.030 |
Why?
|
Pandemics | 1 | 2020 | 739 | 0.030 |
Why?
|
Rats | 1 | 2020 | 3984 | 0.030 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 266 | 0.030 |
Why?
|
Sequence Analysis, DNA | 1 | 2017 | 853 | 0.030 |
Why?
|
PTEN Phosphohydrolase | 1 | 2015 | 128 | 0.030 |
Why?
|
Phosphorylation | 1 | 2016 | 1101 | 0.030 |
Why?
|
Genetic Association Studies | 1 | 2015 | 294 | 0.030 |
Why?
|
Erlotinib Hydrochloride | 1 | 2013 | 90 | 0.030 |
Why?
|
Immunoblotting | 1 | 2013 | 267 | 0.030 |
Why?
|
Gene Expression Regulation | 2 | 2016 | 1917 | 0.030 |
Why?
|
Software | 1 | 2016 | 650 | 0.030 |
Why?
|
Quinazolines | 1 | 2013 | 220 | 0.030 |
Why?
|
Antibodies, Monoclonal, Humanized | 1 | 2017 | 929 | 0.030 |
Why?
|
Cervix Uteri | 1 | 2011 | 64 | 0.030 |
Why?
|
CpG Islands | 1 | 2011 | 150 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2013 | 859 | 0.020 |
Why?
|
Aurora Kinases | 1 | 2010 | 17 | 0.020 |
Why?
|
Dasatinib | 1 | 2010 | 37 | 0.020 |
Why?
|
Azacitidine | 1 | 2011 | 137 | 0.020 |
Why?
|
src-Family Kinases | 1 | 2010 | 74 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2010 | 105 | 0.020 |
Why?
|
Embryo, Mammalian | 1 | 2010 | 207 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 2010 | 314 | 0.020 |
Why?
|
United States | 1 | 2022 | 6637 | 0.020 |
Why?
|
Models, Biological | 1 | 2016 | 1748 | 0.020 |
Why?
|
Cell Adhesion | 1 | 2010 | 418 | 0.020 |
Why?
|
Adolescent | 1 | 2022 | 8968 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2010 | 302 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2010 | 679 | 0.020 |
Why?
|
Cell Cycle | 1 | 2010 | 502 | 0.020 |
Why?
|
Transformation, Genetic | 1 | 2007 | 40 | 0.020 |
Why?
|
DNA, Recombinant | 1 | 2007 | 67 | 0.020 |
Why?
|
Cell Line | 1 | 2011 | 2466 | 0.020 |
Why?
|
Gene Library | 1 | 2007 | 130 | 0.020 |
Why?
|
Polyphenols | 1 | 2006 | 13 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 2267 | 0.020 |
Why?
|
Plant Preparations | 1 | 2006 | 19 | 0.020 |
Why?
|
Phenols | 1 | 2006 | 40 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2007 | 266 | 0.020 |
Why?
|
Plasmids | 1 | 2007 | 287 | 0.020 |
Why?
|
Flavonoids | 1 | 2006 | 85 | 0.020 |
Why?
|
DNA Primers | 1 | 2007 | 542 | 0.020 |
Why?
|
Drug Synergism | 1 | 2006 | 303 | 0.020 |
Why?
|
Leukemia, Myeloid | 1 | 2006 | 249 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2006 | 1047 | 0.010 |
Why?
|
Saccharomyces cerevisiae | 1 | 2007 | 434 | 0.010 |
Why?
|
Cell Communication | 1 | 2003 | 194 | 0.010 |
Why?
|
Cell Division | 1 | 2003 | 696 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2006 | 1958 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2007 | 3029 | 0.010 |
Why?
|
Calcium | 1 | 2006 | 1148 | 0.010 |
Why?
|
Retrospective Studies | 1 | 2015 | 8431 | 0.010 |
Why?
|
Cell Cycle Proteins | 1 | 2003 | 388 | 0.010 |
Why?
|